Literature DB >> 31219185

T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.

Michael D Keller1,2, Sam Darko3, Haili Lang2, Amy Ransier3, Christopher A Lazarski2, Yunfei Wang4, Patrick J Hanley2,5, Blachy J Davila5, Jennifer R Heimall6, Richard F Ambinder7, A John Barrett8, Cliona M Rooney9, Helen E Heslop9, Daniel C Douek3, Catherine M Bollard2,5.   

Abstract

Viral infections are a serious cause of morbidity and mortality following haematopoietic stem cell transplantation (HSCT). Adoptive cellular therapy with virus-specific T cells (VSTs) has been successful in preventing or treating targeted viruses in prior studies, but the composition of ex vivo expanded VST and the critical cell populations that mediate antiviral activity in vivo are not well defined. We utilized deep sequencing of the T-cell receptor beta chain (TCRB) in order to classify and track VST populations in 12 patients who received VSTs following HSCT to prevent or treat viral infections. TCRB sequencing was performed on sorted VST products and patient peripheral blood mononuclear cells samples. TCRB diversity was gauged using the Shannon entropy index, and repertoire similarity determined using the Morisita-Horn index. Similarity indices reflected an early change in TCRB diversity in eight patients, and TCRB clonotypes corresponding to targeted viral epitopes expanded in eight patients. TCRB repertoire diversity increased in nine patients, and correlated with cytomegalovirus (CMV) viral load following VST infusion (P = 0·0071). These findings demonstrate that allogeneic VSTs can be tracked via TCRB sequencing, and suggests that T-cell receptor repertoire diversity may be critical for the control of CMV reactivation after HSCT.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  T-lymphocyte; adoptive immunotherapy; haematopoietic stem cell transplantation; viral infection

Mesh:

Substances:

Year:  2019        PMID: 31219185      PMCID: PMC6786907          DOI: 10.1111/bjh.16053

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  42 in total

1.  Human syndromes of immunodeficiency and dysregulation are characterized by distinct defects in T-cell receptor repertoire development.

Authors:  Xiaomin Yu; Jorge R Almeida; Sam Darko; Mirjam van der Burg; Suk See DeRavin; Harry Malech; Andrew Gennery; Ivan Chinn; Mary Louise Markert; Daniel C Douek; Joshua D Milner
Journal:  J Allergy Clin Immunol       Date:  2014-01-07       Impact factor: 10.793

2.  Rapid salvage treatment with virus-specific T cells for therapy-resistant disease.

Authors:  Michael Uhlin; Jens Gertow; Mehmet Uzunel; Mantas Okas; Sofia Berglund; Emma Watz; Mats Brune; Per Ljungman; Mark Maeurer; Jonas Mattsson
Journal:  Clin Infect Dis       Date:  2012-07-17       Impact factor: 9.079

3.  Frequent contribution of T cell clonotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: application to direct detection of their molecular imprint on the human peripheral T cell repertoire.

Authors:  A Lim; L Trautmann; M A Peyrat; C Couedel; F Davodeau; F Romagné; P Kourilsky; M Bonneville
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

4.  Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses.

Authors:  Lydie Trautmann; Marie Rimbert; Klara Echasserieau; Xavier Saulquin; Bérangère Neveu; Julie Dechanet; Vincenzo Cerundolo; Marc Bonneville
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

5.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

6.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Authors:  Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

Review 7.  T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Authors:  Catherine M Bollard; Helen E Heslop
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

8.  Methods for diversity and overlap analysis in T-cell receptor populations.

Authors:  Grzegorz A Rempala; Michal Seweryn
Journal:  J Math Biol       Date:  2012-09-25       Impact factor: 2.259

Review 9.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Authors:  Mitchell R Smith
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 10.  The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.

Authors:  Francesco Saglio; Patrick J Hanley; Catherine M Bollard
Journal:  Cytotherapy       Date:  2014-02       Impact factor: 5.414

View more
  11 in total

1.  T-cell tracking, safety, and effect of low-dose donor memory T-cell infusions after αβ T cell-depleted hematopoietic stem cell transplantation.

Authors:  Sergey Blagov; Ivan V Zvyagin; Larisa Shelikhova; Rimma Khismatullina; Dmitriy Balashov; Ekaterina Komech; Viktoria Fomchenkova; Mikhail Shugay; Julia Starichkova; Elena Kurnikova; Dmitriy Pershin; Maria Fadeeva; Svetlana Glushkova; Yakov Muzalevskii; Alexei Kazachenok; Maria Efimenko; Elena Osipova; Galina Novichkova; Dmitriy Chudakov; Alexei Maschan; Michael Maschan
Journal:  Bone Marrow Transplant       Date:  2020-11-17       Impact factor: 5.483

2.  Variances in Antiviral Memory T-Cell Repertoire of CD45RA- and CD62L-Depleted Lymphocyte Products Reflect the Need of Individual T-Cell Selection Strategies to Reduce the Risk of GvHD while Preserving Antiviral Immunity in Adoptive T-Cell Therapy.

Authors:  Caroline Mangare; Sabine Tischer-Zimmermann; Agnes Bonifacius; Sebastian B Riese; Anna Christina Dragon; Rainer Blasczyk; Britta Maecker-Kolhoff; Britta Eiz-Vesper
Journal:  Transfus Med Hemother       Date:  2021-09-10       Impact factor: 3.747

3.  Multiple modes of antigen exposure induce clonotypically diverse epitope-specific CD8+ T cells across multiple tissues in nonhuman primates.

Authors:  Jennifer Simpson; Carly E Starke; Alexandra M Ortiz; Amy Ransier; Sam Darko; Daniel C Douek; Jason M Brenchley
Journal:  PLoS Pathog       Date:  2022-07-07       Impact factor: 7.464

4.  Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression.

Authors:  Raoul J P Bonnal; Grazisa Rossetti; Enrico Lugli; Marco De Simone; Paola Gruarin; Jolanda Brummelman; Lorenzo Drufuca; Marco Passaro; Ramona Bason; Federica Gervasoni; Giulia Della Chiara; Claudia D'Oria; Martina Martinovic; Serena Curti; Valeria Ranzani; Chiara Cordiglieri; Giorgia Alvisi; Emilia Maria Cristina Mazza; Stefania Oliveto; Ylenia Silvestri; Elena Carelli; Saveria Mazzara; Roberto Bosotti; Maria Lucia Sarnicola; Chiara Godano; Valeria Bevilacqua; Mariangela Lorenzo; Salvatore Siena; Emanuela Bonoldi; Andrea Sartore-Bianchi; Alessio Amatu; Giulia Veronesi; Pierluigi Novellis; Marco Alloisio; Alessandro Giani; Nicola Zucchini; Enrico Opocher; Andrea Pisani Ceretti; Nicolò Mariani; Stefano Biffo; Daniele Prati; Alberto Bardelli; Jens Geginat; Antonio Lanzavecchia; Sergio Abrignani; Massimiliano Pagani
Journal:  Nat Immunol       Date:  2021-05-20       Impact factor: 25.606

Review 5.  Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.

Authors:  Helen E Heslop; Sandhya Sharma; Cliona M Rooney
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

Review 6.  Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.

Authors:  Claudio Annaloro; Fabio Serpenti; Giorgia Saporiti; Giulia Galassi; Francesca Cavallaro; Federica Grifoni; Maria Goldaniga; Luca Baldini; Francesco Onida
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

7.  Case Report: Unmanipulated Matched Sibling Donor Hematopoietic Cell Transplantation In TBX1 Congenital Athymia: A Lifesaving Therapeutic Approach When Facing a Systemic Viral Infection.

Authors:  Maria Chitty-Lopez; Carla Duff; Gretchen Vaughn; Jessica Trotter; Hector Monforte; David Lindsay; Elie Haddad; Michael D Keller; Benjamin R Oshrine; Jennifer W Leiding
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

8.  Cellular therapies for the treatment and prevention of SARS-CoV-2 infection.

Authors:  Susan R Conway; Michael D Keller; Catherine M Bollard
Journal:  Blood       Date:  2022-07-21       Impact factor: 25.476

9.  Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.

Authors:  Hannah Kinoshita; Kenneth R Cooke; Melanie Grant; Maja Stanojevic; C Russell Cruz; Michael Keller; Maria Fernanda Fortiz; Fahmida Hoq; Haili Lang; A John Barrett; Hua Liang; Jay Tanna; Nan Zhang; Abeer Shibli; Anushree Datar; Kenneth Fulton; Divyesh Kukadiya; Anqing Zhang; Kirsten M Williams; Hema Dave; Jeffrey S Dome; David Jacobsohn; Patrick J Hanley; Richard J Jones; Catherine M Bollard
Journal:  Blood Adv       Date:  2022-04-26

Review 10.  Virus-specific T-cell therapies for patients with primary immune deficiency.

Authors:  Michael D Keller; Catherine M Bollard
Journal:  Blood       Date:  2020-02-27       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.